Literature DB >> 22809660

Pathophysiological insights derived by natural history and motor function of spinal muscular atrophy.

Michelle A Farrar1, Steve Vucic, Heather M Johnston, Desirée du Sart, Matthew C Kiernan.   

Abstract

OBJECTIVE: To examine the natural history of spinal muscular atrophy (SMA) to gain further insight into the clinical course and pathogenesis. STUDY
DESIGN: Survival pattern, age of onset, and ambulatory status were retrospectively analyzed in 70 patients with SMA with deletions of the survival motor neuron 1 genes that presented to a specialized neuromuscular clinic. The Kaplan-Meier method was used to obtain survival curves. Hammersmith Functional Motor Scale-Expanded and abductor pollicis brevis compound muscle action potential amplitudes were assessed in 25 of the surviving cohort and correlated with survival motor neuron 2 copy number.
RESULTS: Survival probabilities at ages 1, 2, 4, 10, 20, and 40 years were 40%, 25%, 6%, and 0%, respectively, for patients with SMA type 1; 100%, 100%, 97%, 93%, 93%, and 52% for patients with SMA type 2 and all patients with SMA type 3 were alive (age range 7-33 years). There were significant associations between age of onset and long-term outcome, specifically survival in SMA type 1 (P < .01) and Hammersmith Functional Motor Scale-Expanded (P < .0001), and compound muscle action potential (P = .001) in SMA types 2 and 3. Motor function in patients with long-standing SMA reduced over prolonged periods or remained stable. Survival motor neuron 2 copy number related to continuing changes in motor function with age.
CONCLUSION: The natural history of SMA suggests considerable early loss of motor neurons, with severity related to differences in the number of remaining motor neurons. As the ensuing chronic course in milder phenotypes suggests relative stability of remaining motor neurons, the maximal therapeutic window presents early. Crown
Copyright © 2013. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22809660     DOI: 10.1016/j.jpeds.2012.05.067

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  31 in total

1.  Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden.

Authors:  Santiago Zuluaga-Sanchez; Megan Teynor; Christopher Knight; Robin Thompson; Thomas Lundqvist; Mats Ekelund; Annabelle Forsmark; Adrian D Vickers; Andrew Lloyd
Journal:  Pharmacoeconomics       Date:  2019-06       Impact factor: 4.981

Review 2.  Axonal Excitability in Amyotrophic Lateral Sclerosis : Axonal Excitability in ALS.

Authors:  Susanna B Park; Matthew C Kiernan; Steve Vucic
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

Review 3.  The Genetics of Spinal Muscular Atrophy: Progress and Challenges.

Authors:  Michelle A Farrar; Matthew C Kiernan
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

4.  An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy.

Authors:  Jennifer M Kwon; Kapil Arya; Nancy Kuntz; Han C Phan; Cory Sieburg; Kathryn J Swoboda; Aravindhan Veerapandiyan; Beverly Assman; Silvia Bader-Weder; Travis L Dickendesher; Jennifer Hansen; Helen Lin; Ying Yan; Vamshi K Rao
Journal:  Ann Clin Transl Neurol       Date:  2022-05-14       Impact factor: 5.430

5.  Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial.

Authors:  Kevin A Strauss; Michelle A Farrar; Francesco Muntoni; Kayoko Saito; Jerry R Mendell; Laurent Servais; Hugh J McMillan; Richard S Finkel; Kathryn J Swoboda; Jennifer M Kwon; Craig M Zaidman; Claudia A Chiriboga; Susan T Iannaccone; Jena M Krueger; Julie A Parsons; Perry B Shieh; Sarah Kavanagh; Melissa Wigderson; Sitra Tauscher-Wisniewski; Bryan E McGill; Thomas A Macek
Journal:  Nat Med       Date:  2022-06-17       Impact factor: 87.241

6.  Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study.

Authors:  Astrid Pechmann; Max Behrens; Katharina Dörnbrack; Adrian Tassoni; Franziska Wenzel; Sabine Stein; Sibylle Vogt; Daniela Zöller; Günther Bernert; Tim Hagenacker; Ulrike Schara-Schmidt; Maggie C Walter; Astrid Bertsche; Katharina Vill; Matthias Baumann; Manuela Baumgartner; Isabell Cordts; Astrid Eisenkölbl; Marina Flotats-Bastardas; Johannes Friese; René Günther; Andreas Hahn; Veronka Horber; Ralf A Husain; Sabine Illsinger; Jörg Jahnel; Jessika Johannsen; Cornelia Köhler; Heike Kölbel; Monika Müller; Arpad von Moers; Annette Schwerin-Nagel; Christof Reihle; Kurt Schlachter; Gudrun Schreiber; Oliver Schwartz; Martin Smitka; Elisabeth Steiner; Regina Trollmann; Markus Weiler; Claudia Weiß; Gert Wiegand; Ekkehard Wilichowski; Andreas Ziegler; Hanns Lochmüller; Janbernd Kirschner
Journal:  Orphanet J Rare Dis       Date:  2022-10-23       Impact factor: 4.303

7.  [Is the refusal of invasive or noninvasive ventilation in a child with spinal muscular atrophy ethically justified?]

Authors:  Martina Radner; Annette Henry
Journal:  Wien Med Wochenschr       Date:  2018-02-15

Review 8.  Congenital and childhood myotonic dystrophy: Current aspects of disease and future directions.

Authors:  Genevieve Ho; Michael Cardamone; Michelle Farrar
Journal:  World J Clin Pediatr       Date:  2015-11-08

9.  A mixed methods exploration of families' experiences of the diagnosis of childhood spinal muscular atrophy.

Authors:  Sally Lawton; Chriselle Hickerton; Alison D Archibald; Belinda J McClaren; Sylvia A Metcalfe
Journal:  Eur J Hum Genet       Date:  2014-07-30       Impact factor: 4.246

10.  Skeletal muscle denervation causes skeletal muscle atrophy through a pathway that involves both Gadd45a and HDAC4.

Authors:  Kale S Bongers; Daniel K Fox; Scott M Ebert; Steven D Kunkel; Michael C Dyle; Steven A Bullard; Jason M Dierdorff; Christopher M Adams
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-08-13       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.